If you use this site, please help us out by making a donation today!
SPECIAL NOTE!
Due to the generosity of a long time DrugSense funder, we have secured
a large matching funds grant! This means that anything you contribute
right NOW to DrugSense will be matched 100%, thus doubling the effective
amount of your contribution.
Donate online:
click here and help us out!
Topic:
atomoxetine(1 articles)
Description: Atomoxetine is a selective norepinephrine reuptake inhibitor (SNRI) approved as a less stimulating treatment for ADHD in 2002 (U.S.). The precise mechanism by which it produces its therapeutic effects is unknown, but is thought to be related to its SNRI action. ((-)-N-methyl-3-phenyl-3-(o-tolyloxy)-propylamine)
Content-type: application/atom+xml
breaking drug news - atomoxetine2010-03-20T09:50:40ZDrugSense News Bothttp://drugpolicycentral.com/bot/XML::Atom::SimpleFeedSHIN v. UNIVERSITY OF MARYLAND MEDICAL SYSTEM CORPORATION (US) Shin had written orders for patients that were inappropriate, such as "ordering IV Prednisone, ordering [Fresh Frozen Plasma] on the wrong patient and placing a patient on a standing order of narcotics that cause somnolence." ...2010-03-15T03:34:59Zhttp://drugpolicycentral.com/bot/article/leagle5916.htm
How does this newsbot work for you? We are especially interested in hearing from you about this site. What do you like about it? What don't you like about this site? What would you change about this site? Please write and let us know how we are doing.
![:-] Bot! - home](/bot/images/dsbotface1.gif ":-] Bot! - home")
